Oettel M, Kaufmann G, Kurischko A
JENAPHARM GmbH, Jena.
Pharmazie. 1993 Jul;48(7):541-5.
Two identified metabolites of the orally active progestin dienogest, the compounds STS 749 (17 alpha-cyanomethyl-11 beta,17 beta-dihydroxy-estra-4,9-dien-3-one) and STS 825 (17 alpha-cyanomethyl-estra-1,3,5(10),9(11)-tetraene-3,17 beta-diol), furthermore 4 microbially formed metabolites and 10 chemically prepared analoga of dienogest were characterized by endocrinological tests. The compounds were investigated for progesterone-receptor binding, progestational and antiprogestational, estrogenic and antigonadotropic activities, furthermore for inhibition of fertility. In no case an increased progestational activity of metabolites or analoga was found, compared to the parent substance. Therefore, it should be excluded, that dienogest acts as a prodrug. Additionally, the dosages necessary to produce the progestational effects are quite similar using oral or subcutaneous application. Therefore, a first-pass effect can be neglected. Regarding the low endocrine side effects of dienogest, the antiprogestational activity may be caused, at least in part, by metabolites.
口服活性孕激素地诺孕素的两种已鉴定代谢物,即化合物STS 749(17α-氰甲基-11β,17β-二羟基-雌甾-4,9-二烯-3-酮)和STS 825(17α-氰甲基-雌甾-1,3,5(10),9(11)-四烯-3,17β-二醇),此外,还有4种微生物形成的代谢物和10种化学合成的地诺孕素类似物通过内分泌学试验进行了表征。对这些化合物进行了孕酮受体结合、孕激素和抗孕激素、雌激素和抗促性腺激素活性的研究,此外还研究了对生育力的抑制作用。与母体物质相比,在任何情况下都未发现代谢物或类似物的孕激素活性增加。因此,应排除地诺孕素作为前药的作用。此外,口服或皮下给药产生孕激素作用所需的剂量相当相似。因此,首过效应可以忽略不计。鉴于地诺孕素的内分泌副作用较低,抗孕激素活性可能至少部分由代谢物引起。